Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biogen Inc (BIIB)

Biogen Inc (BIIB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 44,592,164
  • Shares Outstanding, K 149,033
  • Annual Sales, $ 13,445 M
  • Annual Income, $ 4,001 M
  • 60-Month Beta 0.41
  • Price/Sales 3.28
  • Price/Cash Flow 8.71
  • Price/Book 4.43
Trade BIIB with:

Options Overview

Details
  • Implied Volatility 36.53%
  • Historical Volatility 28.00%
  • IV Percentile 9%
  • IV Rank 6.02%
  • IV High 120.28% on 06/04/21
  • IV Low 31.16% on 08/12/21
  • Put/Call Vol Ratio 0.99
  • Today's Volume 2,753
  • Volume Avg (30-Day) 4,393
  • Put/Call OI Ratio 0.88
  • Today's Open Interest 62,570
  • Open Int (30-Day) 60,901

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 4.21
  • Number of Estimates 28
  • High Estimate 4.69
  • Low Estimate 3.65
  • Prior Year 8.84
  • Growth Rate Est. (year over year) -52.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
294.34 +1.82%
on 09/14/21
351.86 -14.83%
on 08/18/21
-43.81 (-12.75%)
since 08/16/21
3-Month
294.34 +1.82%
on 09/14/21
396.89 -24.49%
on 06/17/21
-91.62 (-23.41%)
since 06/16/21
52-Week
223.25 +34.24%
on 11/09/20
468.55 -36.04%
on 06/07/21
+23.30 (+8.43%)
since 09/16/20

Most Recent Stories

More News
Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy

Vixotrigine, a non-opioid investigational pain drug, has the potential to address significant unmet medical needs of individuals living with chronic painful neuropathy

BIIB : 299.69 (+0.16%)
Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi(R) (risdiplam)

-- Clinical data available to date suggest there are remaining unmet needs in some spinal muscular atrophy (SMA) patients treated with Evrysdi

BIIB : 299.69 (+0.16%)
IONS : 36.43 (-1.43%)
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

Sector ETF report for PBE

PBE : 76.65 (+0.34%)
BIIB : 299.69 (+0.16%)
ILMN : 449.92 (+0.01%)
IBB : 172.51 (+0.41%)
CTLT : 138.17 (-0.07%)
XBI : 131.00 (+0.44%)
Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Biogen Inc. (BIIB) closed at $295.95, marking a -1.98% move from the previous day.

BIIB : 299.69 (+0.16%)
DiaMedica (DMAC) Initiates Pivotal Ischemic Stroke Study

DiaMedica (DMAC) is developing its recombinant KLK1 protein candidate, DM199 for treating patients who suffered an acute ischemic stroke in the last 24 hours as well as for reducing the risk of recurrent...

BIIB : 299.69 (+0.16%)
PFE : 44.47 (-0.67%)
ABBV : 108.08 (+0.29%)
DMAC : 4.05 (+4.65%)
Biogen (BIIB) Alzheimer's Drug Aduhelm Sees Slow Launch, Stock Down

Biogen's (BIIB) new Alzheimer's drug, Aduhelm, can bring in huge revenues, if successfully commercialized.

BIIB : 299.69 (+0.16%)
LLY : 231.04 (-1.15%)
SAVA : 43.95 (+0.07%)
ANVS : 31.24 (-3.16%)
Stocks Retreat on Concern About Stimulus Tapering

What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Thursday closed down -0.46%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.43%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed...

$SPX : 4,473.75 (-0.16%)
SPY : 447.17 (-0.16%)
$DOWI : 34,751.32 (-0.18%)
DIA : 348.18 (-0.18%)
$IUXX : 15,515.91 (+0.08%)
QQQ : 378.31 (+0.07%)
BIIB : 299.69 (+0.16%)
LLY : 231.04 (-1.15%)
REGN : 653.18 (+0.18%)
AMGN : 217.36 (-0.35%)
DLR : 156.41 (+0.25%)
NTES : 84.34 (-0.73%)
JD : 77.17 (+0.70%)
BABA : 156.26 (-1.01%)
MRNA : 440.65 (+1.42%)
LULU : 426.44 (+1.79%)
ZNZ21 : 133-025 (unch)
Dementia and Alzheimer's Disease to Attain a Significant CAGR during 2022-2027; Increasing Adoption of Cloud Technologies to Boost the Market Growth

Research Nester released a report titled ": Global Demand Analysis & Opportunity Outlook 2028"which delivers detailed overview of the global dementia and Alzheimer's disease treatment market in terms of...

NOVN : 8.45 (-1.63%)
PFE : 44.47 (-0.67%)
ABBV : 108.08 (+0.29%)
AGN : 193.02 (+0.02%)
LLY : 231.04 (-1.15%)
AZN.LN : 8,141.000 (+0.20%)
BIIB : 299.69 (+0.16%)
INMB : 18.07 (+3.49%)
Spinal Muscular Atrophy Treatment Market Key Players, Industry Overview and Forecasts to 2028

Research Nester published a report titled  which delivers a detailed overview of the Spinal muscular atrophy drug market in terms of market segmentation by treatment, by route of administration, by disease...

NOVN : 8.45 (-1.63%)
PFE : 44.47 (-0.67%)
BIIB : 299.69 (+0.16%)
PTCT : 40.59 (+0.07%)
VYGR : 3.03 (+0.66%)
CYTK : 33.49 (-0.62%)
IONS : 36.43 (-1.43%)
REGN : 653.18 (+0.18%)
Dementia and Alzheimer's Disease Treatment Market Top Companies, Business Growth, Size, and Forecast 2028

Research Nester released a report titled ": Global Demand Analysis & Opportunity Outlook 2028"which delivers detailed overview of the global dementia and Alzheimer's disease treatment market in terms of...

NOVN : 8.45 (-1.63%)
PFE : 44.47 (-0.67%)
ABBV : 108.08 (+0.29%)
AGN : 193.02 (+0.02%)
LLY : 231.04 (-1.15%)
AZN.LN : 8,141.000 (+0.20%)
BIIB : 299.69 (+0.16%)
INMB : 18.07 (+3.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Key Turning Points

3rd Resistance Point 308.98
2nd Resistance Point 305.96
1st Resistance Point 302.82
Last Price 299.69
1st Support Level 296.66
2nd Support Level 293.64
3rd Support Level 290.50

See More

52-Week High 468.55
Fibonacci 61.8% 374.85
Fibonacci 50% 345.90
Fibonacci 38.2% 316.95
Last Price 299.69
52-Week Low 223.25

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar